Adeno-associated virus, or AAV, is a small, single-stranded DNA virus that has become a popular tool for gene therapy due to its low pathogenicity and ability to efficiently deliver genes to a variety of cell types. One of the advantages of AAV is its ability to target specific tissues or cell types by modifying the viral capsid, which is the protein shell that encloses the viral genome.

Scientists have found that by engineering AAV capsids, they can selectively target certain cell types, including those in the eye. This has made AAV a promising candidate for gene therapy applications in ophthalmology.

One of the reasons why AAV is well-suited for eye gene therapy is its ability to infect non-dividing cells. Many cells in the eye, including retinal cells, do not actively divide, making it challenging to deliver genes using traditional methods. AAV, however, can efficiently transduce these non-dividing cells, allowing for sustained expression of therapeutic genes.

Additionally, AAV has a low risk of insertional mutagenesis, which means that it is less likely to cause harmful genetic alterations when integrating into the host cell's genome. This safety profile makes AAV an attractive choice for gene therapy in the eye, where precision and minimal side effects are essential.

Researchers have been investigating the use of AAV for the treatment of various eye diseases, including inherited retinal disorders, age-related macular degeneration, and corneal dystrophies. Clinical trials using AAV-based gene therapies have shown promising results, demonstrating the potential of this approach for restoring vision and improving the quality of life for patients with eye diseases.

Overall, the ability of AAV to target specific eye tissues and its low risk of adverse effects make it a valuable tool for gene therapy in ophthalmology, offering new hope for the treatment of previously untreatable eye conditions.